Anne-Marie Koop

3 151 Zuurbier, Department of Anesthesiology, Laboratory of Experimental Intensive Care and Anesthesiology, AMC, Amsterdam, Netherlands; 2015;16. 80. Bruns DR, Dale Brown R, Stenmark KR, Buttrick PM, Walker LA. Mitochondrial integrity in a neonatal bovine model of right ventricular dysfunction. Am J Physiol - Lung Cell Mol Physiol L.A. Walker, Univ. of Colorado-Denver, Dept. of Medicine, Cardiology, Aurora, United States; 2015;308:L158–L167. 81. Kaur G, Singh N, Lingeshwar P, Siddiqui HH, Hanif K. Poly (ADP-ribose) polymerase-1: An emerging target in right ventricle dysfunction associated with pulmonary hypertension. Pulm Pharmacol Ther K. Hanif, Division of Pharmacology, CSIR-Central Drug Research Institute, Lucknow, India; 2015;30:66–79. 82. Aziz A, Lee AM, Ufere NN, Damiano RJ, Townsend RR, Moon MR. Proteomic Profiling of Early Chronic Pulmonary Hypertension: Evidence for Both Adaptive and Maladaptive Pathology. J Pulm Respir Med United States; 2015;5. 83. Graham BB, Kumar R, Mickael C, Sanders L, Gebreab L, Huber KM, Perez M, Smith-Jones P, Serkova NJ, Tuder RM. Severe pulmonary hypertension is associated with altered right ventricle metabolic substrate uptake. Am J Physiol - Lung Cell Mol Physiol B.B. Graham, Division of Pulmonary Sciences and Critical Care Medicine, Univ. of Colorado Denver, Aurora, United States; 2015;309:L435–L440. 84. Khan SS, Cuttica MJ, Beussink-Nelson L, Kozyleva A, Sanchez C, Mkrdichian H, Selvaraj S, Dematte JE, Lee DC, Shah SJ. Effects of ranolazine on exercise capacity, right ventricular indices, and hemodynamic characteristics in pulmonary arterial hypertension: a pilot study. Pulm Circ United States; 2015;5:547–556. 85. Sakao S, Miyauchi H, Voelkel NF, Sugiura T, Tanabe N, Kobayashi Y, Tatsumi K. Increased right ventricular fatty acid accumulation in chronic thromboembolic pulmonary hypertension. Ann Am Thorac Soc S. Sakao, Department of Respirology (B2), Graduate School of Medicine, Chiba University, Chuo-ku, Chiba, Japan; 2015;12:1465–1472. 86. Li W, Wang L, Xiong C-M, Yang T, Zhang Y, Gu Q, Yang Y, Ni X-H, Liu Z-H, Fang W, He J-G. The Prognostic Value of 18F-FDG Uptake Ratio Between the Right and Left Ventricles in Idiopathic Pulmonary Arterial Hypertension. Clin Nucl Med 2015;40:859–863. 87. Drozd K, Ahmadi A, Deng Y, Jiang B, Petryk J, Thorn S, Stewart D, Beanlands R, DeKemp RA, DaSilva JN, Mielniczuk LM. Effects of an endothelin receptor antagonist, Macitentan, on right ventricular substrate utilization and function in a Sugen 5416/hypoxia rat model of severe pulmonary arterial hypertension. J Nucl Cardiol L.M. Mielniczuk, Division of Cardiology, Department of Medicine, University of Ottawa Heart Institute, Ottawa, Canada; 2016;1–11. 88. Brittain EL, Talati M, Fessel JP, Zhu H, Penner N, Calcutt MW, West JD, Funke M, Lewis GD, Gerszten RE, Hamid R, Pugh ME, Austin ED, Newman JH, Hemnes AR. Fatty acid metabolic defects and right ventricular lipotoxicity in human pulmonary arterial hypertension. Circulation E.L. Brittain, Division of Cardiovascular Medicine, Vanderbilt University Medical School, Nashville, United States; 2016;133:1936–1944. 89. Talati MH, Brittain EL, Fessel JP, Penner N, Atkinson J, Funke M, Grueter C, Jerome WG, Freeman M, Newman JH, West J, Hemnes AR. Mechanisms of Lipid Accumulation in the Bone Morphogenetic Protein Receptor Type 2 Mutant Right Ventricle. Am J Respir Crit Care Med United States; 2016;194:719–728.